Dana-Farber Cancer Institute: Mark Kieran, M.D., Ph.D. “Discovering new treatments for Malignant Supratentorial High-Grade Gliomas (HGG) and Diffuse Intrinsic Pontine Glioma (DIPG)”
This study consists of developing new target and immune therapies for pediatric gliomas. The drugs to be developed will target tumor cell aberrations including the histone mutation H3.3K27M and abnormalities in the PDGFR, EFGR, and PI3K cell signaling cascades. The drugs will also be screened for their capacities to penetrate the blood-brain barrier using a novel method recently developed at DFCI. This study is meant to provide preclinical models, which can lead to clinical trials of the drugs developed.